cagrisema semaglutide Coadministered Cagrilintide and in Adults with Overweight or Obesity HCPLive - CagriSema, a fixed

Arenson, D

GLP-1 Semaglutide Semaglutide is a prescription treatment used in programs focused on weight management and appetite support for adults

Semaglutide Phase 3 Results (STEP 1) The Phase 3 STEP 1 trial enrolled 1,961 adults with overweight or obesity (BMI 27 with comorbidities or BMI 30) without diabetes (Wilding 2021, NEJM): 2.4 mg weekly: 14.9% body weight reduction at 68 weeks Placebo arm: 2.4% body weight reduction at 68 weeks Responder rates: 86% of subjects on semaglutide achieved 5% weight reduction

Lose up to 20% body weight WEIGHT LOSS Innovative weight loss: designed uniquely for you Unlock next-gen weight loss with Semaglutide